BioScrip (BIOS) Misses Q4 EPS by 5c

BioScrip (NASDAQ: BIOS) reported Q4 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $243.8 million versus the consensus estimate of $238.3 million.

Same store revenue growth (excluding closed locations) for the quarter grew $10.3 million or 4.4% year over year on the strength of same store patient census growth of 8.4% for the same year over year period.

GUIDANCE:

BioScrip sees FY2016 EPS of ($0.39)-($0.19), versus the consensus of ($0.12).

For earnings history and earnings-related data on BioScrip (BIOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c